{"paper_id":"ce1f0393-d487-4ec2-a658-48b2373d4f0c","body_text":"Abstract\nMenorrhagia affects the lives of many women. The assessment of menstrual flow is highly subjective and gauging the severity of the condition by objective assessment of menstrual blood loss is impractical. In treating menorrhagia, the primary aim should be to improve quality of life. Women are willing to undergo quite invasive treatment in order to achieve this. Drug therapy is the initial treatment of choice and the only option for those who wish to preserve their reproductive function. Despite the availability of a number of drugs, there is a general lack of an evidence-based approach, marked variation in practice and continuing uncertainty regarding the most appropriate therapy. Adverse effects and problems with compliance also undermine the success of medical treatment. This article reviews the available literature to compare the efficacy and tolerability of different medical treatments for menorrhagia.\nTranexamic acid and mefenamic acid are among the most effective first-line drugs used to treat menorrhagia. Despite being used extensively in the past, oral luteal phase norethisterone is probably one of the least effective agents. Women requiring contraception have a choice of the combined oral contraceptive pill, levonorgestrel-releasing intrauterine system (LNG-IUS) or long-acting progestogens. Danazol, gestrinone and gonadotropin-releasing hormone analogues are all effective in terms of reducing menstrual blood loss but adverse effects and costs limit their long-term use. They have a role as second-line drugs for a short period of time in women awaiting surgery.\nWhile current evidence suggests that the LNG-IUS is an effective treatment, further evaluation, including long-term follow up, is awaited. Meanwhile, the quest continues for the ideal form of medical treatment for menorrhagia — one that is effective, affordable and acceptable.\nSimilar content being viewed by others\nNotes\nThe use of tradenames is for product identification purposes only and does not imply endorsement.\nReferences\nPeto V, Coulter A, Bond A. Factors affecting general practitioners’ recruitment of patients in a prospective study. Fam Pract 1993; 10(2): 207–11\nMcpherson A, Andersson ABM, editors. Women’s problems in general practice. Oxford: Oxford University Press, 1983: 21–41\nBradlow J, Coulter A, Brooks P. Patterns of referral. Oxford: Oxford Health Services Research Unit, 1992\nShaw RW. Assessment of medical treatments of menorrhagia. Br J Obstet Gynaecol 1994; 101Suppl. 11: 15–8\nHallberg L, Hogdahl AM, Nilsson L, et al. Menstrual blood loss: a population study. Acta Obstet Gynecol Scand 1966; 45: 320–51\nCole S, Billewicz W, Thomson A. Sources of variation in the menstrual blood loss. J Obstet Gynaecol Br Commonw 1971; 78: 933–9\nHaynes P, Hodgeson H, Anderson A, et al. Measurement of menstrual blood loss in patients complaining of menorrhagia. Br J Obstet Gynaecol 1977; 84: 763–8\nMarket and Research International (MORI.) Women’s health in 1990. Market Opinion and Research International, 1990. (Research study conducted on behalf of Parke-Davis Laboratories)\nCameron IT. Menstrual disorders. In: Edmonds DK, editor. Dewhursts textbook of obstetrics and gynaecology. 6th ed. Boston: Blackwell Science, 1999: 410–419\nCoulter A, Peto V, Jenkinson C. Quality of life and patient satisfaction following treatment of menorrhagia. Fam Pract 1994; 11: 394–401\nCoulter A, Bradlow J, Agass M, et al. Outcome of referrals to gynaecology outpatients clinics for menstrual problems: an audit of general practice records. Br J Obstet Gynaecol 1991; 98: 789–96\nGath D, Cooper P, Day A. Hysterectomy and psychiatric disorder: 1. Levels of psychiatric morbidity before and after hysterectomy. Br J Psychiatry 1982; 140: 335–40\nClarke A, Black N, Rowe P, et al. Indications for and outcome of total abdominal hysterectomy for benign disease; a prospective cohort study. Br J Obstet Gynaecol 1995; 102: 611–20\nCooper KG, Jack SA, Parkin DE, et al. Five-year follow up of women randomised to medical management or transcervical resection of endometrium for heavy menstrual loss. Br J Obstet Gynaecol 2001; 108: 1222–8\nPrentice A. Medical management of menorrhagia. BMJ 1999; 319: 1343–5\nCoulter A, Kelland J, Peto V, et al. Treating menorrhagia in primary care: an overview of drug trials and survey of prescribing practice. Int J Technol Assess Health Care 1995; 11: 456–71\nLethaby A, Farquhar C, Cook I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Systematic Review. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue. Oxford: Update Software, 2000\nRees MCP, DiMarzo V, Tippins JR, et al. Leukotreine release by endometrium and myometrium throughout the menstrual cycle in dysmenorrhoea and menorrhagia. J Endocrinol 1987; 113: 291–5\nRees MCP, Canete-Solar R, Lopez Bernal A, et al. Effects of fenamates on prostaglandin E receptor binding. Lancet 1988; II: 541–2\nCameron IT. Medical management of menorrhagia. Curr Opin Obstet Gynecol 1992; 2: 136–40\nAnderson ABM, Hynes PJ, Guillebaud J, et al. Reduction of menstrual blood loss by prostaglandin synthetase inhibitors. Lancet 1976: 21: 774–6\nFraser IS, Pearse C, Shearman RP, et al. Efficacy of mefenamic acid in patients with a complaint of menorrhagia. Obstet Gynecol 1981; 58: 543–51\nFraser IS, McCarron G, Markham R, et al. Measured menstrual blood loss in women with menorrhagia associated with pelvic disease and coagulation disorder. Obstet Gynecol 1986; 68: 630–3\nFraser IS, McCarron G, Markham R, et al. Longterm treatment of menorrhagia with mefenamic acid. Obstet Gynecol 1983; 61: 109–12\nHigham J, Shaw R. Risk-benefit assessment of drugs used for the treatment of menstrual disorders. Drug Saf 1991; 6(3): 183–91\nFraser IS. Treatment of ovulatory and anovulatory dysfunctional uterine bleeding with oral progestogens. Aust N Z J Obstet Gynaecol 1990; 30: 353–6\nStewart A, Cummins C, Gold L, et al. The effectiveness of levonorgestrel releasing intrauterine system in menorrhagia: a systematic review. Br J Obstet Gynaecol 2001; 108: 74–6\nLethaby AE, Cooke I, Rees M. Progesterone/progestogen releasing intrauterine systems versus either placebo or any other medication for heavy menstrual bleeding. Cochrane systematic review. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue. Oxford: Update Software, 1999\nBhatena RK. Long acting progestogen-only contraceptive injections: an update. Br J Obstet Gynaecol 2001; 108: 3–8\nFraser IS, McCarron G. Randomised trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with complaints of menorrhagia. Aust N Z J Obstet Gynaecol 1991; 31: 66–70\nKhastgir G, Studd J. Choice of treatment for menorrhagia. In: Seth S, Sutton C, editors. Menorrhagia. Oxford: Isis Medical Media, 1999: 299–315\nLethaby A, Augood C, Duckitt K. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Systematic Review. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue. Oxford: Update Software, 1998\nChamberlain G, Freeman R, Price F, et al. A comparative study of ethamsylate and mefenamic acid in dysfunctional uterine bleeding. Br J Obstet Gynaecol 1991; 98: 707–11\nCameron IT, Haining R, Lumsden MA, et al. The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstet Gynecol 1990; 76: 85–8\nCameron IT, Leask R, Kelly RW, et al. Effects of danazol, mefenamic acid, norethisterone and a progesterone-impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins 1987; 34: 99–110\nDockeray CJ, Sheppard BL, Bonnar J. Comparison between mefenamic acid and danazol in the treatment of established menorrhagia. Br J Obstet Gynaecol 1989; 96: 840–4\nGrover V, Usha R, Gupta U, et al. Management of cyclical menorrhagia with prostaglandin synthetase inhibitor. Asia Oceania J Obstet Gynaecol 1990; 16: 255–9\nHall P, Maclachlan N, Thorn N, et al. Control of menorrhagia by the cyclo-oxygenase inhibitors naproxen sodium and mefenamic acid. Br J Obstet Gynaecol 1987; 94: 554–8\nBonnar J, Sheppard B. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid and tranexamic acid. BMJ 1996; 313: 579–82\nEdlund M, Anderson K, Rybo G, et al. Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi 2161). Br J Obstet Gynaecol 1995; 102: 913–7\nCallender ST, Warner GT, Cope E. Treatment of menorrhagia with tranexamic acid: a double blind trial. BMJ 1970; 4: 214–6\nPreston JT, Cameron IT, Adams EJ, et al. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol 1995; 102: 401–5\nLethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy menstrual bleeding. Cochrane systematic review. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue. Oxford: Update Software, 1998\nMilsom I, Anderson K, Andersch B, et al. A comparison of flurbiprofen, tranexamic acid and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorhagia. Am J Obstet Gynecol 1991; 164: 879–83\nIrvine GA, Campbell-Brown MB, Lumsden MA, et al. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol 1998; 105(6): 592–8\nCrosignani PG, Vercellini P, Mosconi P, et al. Levonorgestrel releasing intrauterine device versus hysteroscopic endometrial resection in treatment of dysfunctional uterine bleeding. Obstet Gynecol 1997; 90: 257–63\nKittleson N, Istre O. A randomised study comparing Levonorgestrel intrauterine system (LNG IUS) and transcervical resection of endometrium (TCRE) in the treatment of menorrhagia: preliminary results. Gynecol Endocrinol 1998; 7: 61–5\nBritish National Formulary. British Medical Association and Royal Pharmaceutical Society of Great Britain. London 2002 Mar; 43: 475–6\nAndersch B, Milsom I, Rybo G. An objective evaluation of flurbiprofen and tranexamic acid in the treatment of idiopathic menorrhagia. Acta Obstet Gynecol Scand 1988; 67: 645–8\nEffective Health Care. The management of menorrhagia. NHS Centre for Reviews and Dissemination, University of York, Research Unit, Royal College of Physicians 1995 (1)\nRybo G. Tranexamic acid therapy effective treatment in heavy menstrual bleeding: clinical update. Thera Adv 1991; 4: 1–8\nRoyal College of Obstetricians and Gynaecologists. The initial management of menorrhagia: RCOG evidence based clinical guidelines No. 1. London, 1998\nFender GRK, Prentice A, Gorst T, et al. Randomised controlled trial of educational package on management of menorrhagia in primary care: the Anglia Menorrhagia Education Study. BMJ 1999; 318: 1246–50\nBritish National Formulary. British Medical Association and Royal Pharmaceutical Society of Great Britain. London 2002 Mar; 43: 123\nKovacs L, Falkay G. Ethamsylate as inhibitor of prostaglandin biosynthesys in pregnant human myometrium in-vitro. Experientia 1981; 37: 1182–3\nRennie JM, Lam PKL. Effects of ethamsylate on cerebral blood flow velocity in premature babies. Arch Dis Child 1989; 64: 46–7\nJaffe G, Wickham A. A double blind pilot study of dicynene in the control of menorrhagia. J Int Med Res 1973; 1: 127–9\nHarrison RF, Campbell S. A double blind trial of ethamsylate in the treatment of primary and intra-uterine device menorrhagia. Lancet 1976; II: 283–5\nHickey M, Higham J, Fraser IS. Progestogens versus oestrogens and progestogens for irregular uterine bleeding associated with anovulation. Cochrane Systematic Review. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue. Oxford: Update Software, 1998\nBonduelle M, Walker JJ, Calder AA. A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgrad Med J 1991; 67: 833–6\nBuyru F, Yalcin O, Kovanci E, et al. Danazol therapy in dysfunctional uterine bleeding [Turkish]. Istanbul Universitesi Tip Fakultesi Mecmuasi 1995; 58(3): 37–40\nHigham JM, Shaw RW. A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. Am J Obstet Gynecol 1993; 169: 1134–9\nBritish National Formulary. British Medical Association and Royal Pharmaceutical Society of Great Britain. London 2002 Mar; 43: 356\nBergqvist A, Rybo G. Treatment of menorrhagia with intrauterine release of progesterone. Br J Obstet Gynaecol 1983; 90: 255–8\nVan den Hurk PJ, O’Brien PMS. Non-contraceptive use of levonorgestrel-releasing intrauterine system. Obstet Gynecol 1999; 1(1): 13–9\nBackman T, Huhtala S, Blom T, et al. Length and use of symptoms associated with premature removal of the levonorgestrel instruterine system: a nation-wide study of 17,360 users. BJOG. 2000; 107: 335–9\nLahteenmaki P, Haukkamaa M, Puolakka J, et al. Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy. BMJ 1998; 316: 1122–6\nBarrington JW, Bowen-Simpkins P. The levonorgestrel intrauterine system in the management of menorrhagia. Br J Obstet Gynaecol 1997; 104: 614–6\nBritish National Formulary. British Medical Association and Royal Pharmaceutical Society of Great Britain. London 2002; 43 Mar: 393–394\nHurskainen R, Teperi J, Rissanen P, et al. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial: early report. Lancet 2001; 357: 273–7\nEuroQol Group. EuroQol: a new facility for the treatment of health-related quality of life. Health Policy 1990; 16: 199–208\nBritish National Formulary. British Medical Association and Royal Pharmaceutical Society of Great Britain. London 2002 Mar; 43: 357\nWorking party on behalf of the National Health Committee. Guidelines for management of heavy menstrual bleeding. Wellington: National Health Committee, 1998\nNagrani R, Bowen-Simpkins P, Barrington JW. Can levonorgestrel intrauterine system replace surgical treatment for the management of menorrhagia? Br J Obstet Gynaecol 2002; 109: 345–7\nThe Royal College of Obstetricians and Gynaecologists. The management of menorrhagia in secondary care. National evidence-based clinical guidelines. RCOG, 1999\nBelsey EM. Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception. Contraception 1988; 38: 181–206\nSchwallie PC, Assenzo JR. Contraceptive use-efficacy study using depo-provera administered as an injection every 90 days. Fertil Steril 1973; 24: 331–42\nFraser IS. A survey of different approaches to management of menstrual disturbances in women using injectable contraceptives. Contraception 1983; 28: 385–97\nRowlands S, Dakin L. Twelve years of injectable contraceptive use in general practice. Br J Fam Plann 1998; 23: 133–4\nPaul C, Skegg DC, Williams S. Depot medroxyprogesterone acetate: patterns of use and reasons for discontinuation. Contraception 1997; 56(4): 209–14\nWorld Health Organisation. A multicentered phase III comparative clinical trial of depot-medroxyprogesterone acetate given three monthly at doses of 100mg or 150mg: contraceptive efficacy and side effects [abstract]. Contraception 1986; 34: 223\nWorld Health Organisation. Multinational comparative evaluation of two long acting contraceptive steroids: norethisterone enanthate and medroxyprogesterone acetate: final report [abstract]. Contraception 1983; 28: 1\nCromer BA, Smith RD, Blair JM, et al. A prospective study of adolescents who chose among levonorgestrel implant, medroxy-progesterone acetate or the combined oral contraceptive pill as contraception. Pediatrics 1994; 94: 687–94\nAmataykul K, Siarasonboon B, Thanangkul O. A study of mechanism of weight gain in medroxyprogesterone users. Contraception 1980; 22: 605–22\nMatson SC, Henderson KA, McGrath GJ. Physical findings and symptoms of depot-medroxyprogesterone acetate use in adolescent females. J Pediatr Adolesc Gynecol 1997; 10: 18–23\nCundy T, Evans M, Roberts H, et al. Bone density in women receiving depot medroxy progesterone for contraception. BMJ 1991; 303: 13–6\nGuillebaud J. Oestrogen free hormonal contraception. In: Guillebaud J, editor. Contraceptions: your questions answered. Edinburgh: Churchill Livingstone, 1999: 311–6, 328-9\nMishell Jr DR. Noncontraceptive health benefits of oral steroidal contraceptives. Am J Obstet Gynecol 1982; 142: 809–16\nIyer V, Farquhar C, Jepson R. Oral contraceptive pills for heavy menstrual bleeding. Cochrane Systematic Review. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; Issue 2. Oxford: Update Software, 1997\nNilsson L, Solvell L. Clinical studies in oral contraceptives: a randomised double blind crossover study of 4 different preparations. Acta Obstet Gynecol Scand 1967; 46Suppl. 8: 1–31\nNilsson L, Rybo G. Treatment of menorrhagia. Am J Obstet Gynecol 1971; 110: 713–20\nHefnawi F, Askalani H, Zaki K. Menstrual blood loss with copper intrauterine devices. Contraception 1974; 9: 133–9\nCallard GV, Litofswky FS, De Merre LJ. Menstruation in women with normal or artificially controlled cycles. Fertil Steril 1966; 17: 684–8\nRoyal College of General Practitioners. Oral contraceptive and health. London: Pitman Medical, 1974\nRamacharan S, Pelligrin FA, Ray MR, et al. The Walnut Creek Contraceptive Drug Study: a prospective study of the side effects of oral contraceptives. Volume III. An interim report: a comparison of disease occurrence leading to hospitalisation or death in users or non users of oral contraceptives. J Reprod Med 1980; 25Suppl. 6: 345–72\nBritish National Formulary. British Medical Association and Royal Pharmaceutical Society of Great Britain. London 2002 Mar; 43: 386–9\nGray RH. Patterns of bleeding associated with the use of steroidal contraceptives. In: Diczfalusy E, Fraser IS, Webb FTG, editors. Endometrial bleeding and steroidal contraception. Bath: Pitman Press, 1980: 14–49\nSperoff L, Glass RH, Case N. Endometriosis. In: Speroff L, Glass RH, Case N, editors. Clinical gynaecologic endocrinology and infertility. 6th ed. Baltimore: Lippincot Williams & Wilkins, 1999: 1064\nBarbieri RL, Osathanondh R, Ryan KJ. Danazol inhibition of steroidogenesis in human corpus luteum. Obstet Gynecol 1981; 57: 722–4\nNeed JA, Forbes KL, Millazzo L, et al. Danazol in the treatment of menorrhagia: the effect of 1 month induction dose (200mg) and 2 months of maintenance therapy (200mg, 100mg, 50mg or placebo). Aust N Z J Obstet Gynaecol 1992; 32: 346–52\nChimbira TH, Anderson AB, Naish C, et al. Reduction of menstrual blood loss by danazol in menorrhagia: lack of effect of placebo. Br J Obstet Gynaecol 1980; 87: 1152–8\nChimbira TH, Cope E, Anderson AB, et al. The effect of danazol on menorrhagia, coagulation mechanism, haematological indices and body weight. Br J Obstet Gynaecol 1979; 86: 46–50\nBeaumont H, Augood C, Duckitt K. Danazol for heavy menstrual bleeding. Cochrane systematic review. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue. Oxford: Update Software, 2002\nLamb MP Danazol in menorrhagia: a double blind placebo controlled trial. J Obstet Gynaecol 1987; 7: 212–6\nWardle PG, Whitehead MI, Mills RP. Nonreversible and wide ranging vocal changes after treatment with danazol [abstract]. BMJ 1983; 287: 946\nBritish National Formulary. British Medical Association and Royal Pharmaceutical Society of Great Britain. London 2002 Mar; 43: 372\nBritish National Formulary. British Medical Association and Royal Pharmaceutical Society of Great Britain. London 2002 Mar; 43: 373\nTurnbull AC, Rees MC. Gestrinone in the treatment of menorrhagia. Br J Obstet Gynaecol 1990; 97: 713–5\nShaw RW, Duckitt K. Management of menorrhagia in women of childbearing age. In: Seth S, Sutton C, editors. Menorrhagia. Oxford: Isis Medical Media, 1999: 79–96\nShaw RW, Fraser HM. Use of superactive LHRH agonist in the treatment of menorrhagia. Br J Obstet Gynaecol 1984; 91: 913–6\nMiller RM, Frank RA. Zoladex in the treatment of benign gynaecological disorder: an overview of safety and efficacy. Br J Obstet Gynaecol 1992; 99Suppl. 7: 37–41\nThomas EJ, Okuda KJ, Thomas NM. Combination of GNRH agonist and cyclical HRT for DUB. Br J Obstet Gynaecol 1991; 98: 1155–9\nLilford RJ. Hysterectomy: will it pay the bills in 2007 [editorial]. BMJ 1997; 314: 160–1\nAcknowledgements\nWe would like to thank Lynn Garden and Liz Grant for secretarial assistance. No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflict of interest that are directly relevant to the content of this manuscript.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nRights and permissions\nAbout this article\nCite this article\nRoy, S.N., Bhattacharya, S. Benefits and Risks of Pharmacological Agents Used for the Treatment of Menorrhagia. Drug-Safety 27, 75–90 (2004). https://doi.org/10.2165/00002018-200427020-00001\nPublished:\nIssue date:\nDOI: https://doi.org/10.2165/00002018-200427020-00001","source_license":"CC0","license_restricted":false}